Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | $24.99M | $9.73M | $17.90M | $995.00K | $8.18M | $558.52M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | $80.00K | $5.00K |
| Gross Profit | N/A | N/A | $24.99M | $9.73M | $17.90M | $995.00K | $8.10M | $558.52M |
| Gross Margin | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 99.02% | 100.00% |
| Operating Expenses | $127.61M | $152.04M | $97.54M | $71.16M | $57.09M | $32.38M | $23.07M | $577.40M |
| Operating Income | $-127.61M | $-152.04M | $-72.55M | $-61.43M | $-39.19M | $-31.39M | $-14.96M | $-18.88M |
| Operating Margin | 0.00% | 0.00% | -290.32% | -631.38% | -218.91% | -3154.57% | -182.91% | -3.38% |
| Net Income | $-117.12M | $-142.66M | $-69.79M | $-62.00M | $-36.68M | $-28.14M | $-9.30M | $-33.78M |
| Net Margin | 0.00% | 0.00% | -279.27% | -637.19% | -204.87% | -2827.94% | -113.67% | -6.05% |
| EPS (Basic) | $-21.28 | $-52.96 | $-27.20 | $-32.00 | $-80.16 | $-24.32 | $-4.96 | $-20.16 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |